R-DA-EPOCH-21

DRUG2 trials

Sponsors

National Research Center for Hematology, Russia, Elena N.Parovichnikova

Conditions

Diffuse Large B-Cell LymphomaLymphoma, High-Grade

Phase 3

R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

National Research Center for Hematology, RussiaDiffuse Large B-Cell Lymphoma

Start: 2015-02-28End: 2023-02-28Target: 300Updated: 2016-07-25

R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)

Elena N.ParovichnikovaLymphoma, High-Grade

Start: 2018-03-15End: 2024-03-15Target: 80Updated: 2018-03-27

Related Papers

P1207: MULTICENTER RANDOMIZED CONTROLLED (COMPARATIVE) OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF THE R-DA-EPOCH-21 AND R-MNHL-BFM-90 ± AUTO- HSCT PROGRAMS IN PATIENTS WITH DE NOVO DIFFUSE B-CELL LAR

HemaSphere2022-06-012 citations

PB2130: RATIONAL FOR METHOTREXATE USAGE FOR THE TREATMENT AND PREVENTION OF CNS INVOLVEMENT IN PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMAS.

HemaSphere2022-06-01